This invention provides a method of treating a neurodegenerative disease selected from the group consisting of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, comprising administering a pharmaceutically effective amount of an agent capable of suppressing expression or activity of SHP-1/-2 (Src homology region 2 domain-containing phosphatase-1/-2) or Fc.gamma.RIIB (IgG Fc receptor II-B) to a subject having the neurodegenerative disease, wherein the agent capable of suppressing expression of SHP-1/-2 or Fc.gamma.RIIB is selected from the group consisting of miRNA, siRNA, shRNA, antisense oligonucleotide, and a combination thereof capable of specifically binding to mRNA of SHP-1/-2 or Fc.gamma.RIIB, and the agent capable of suppressing activity of SHP-1/-2 or Fc.gamma.RIIB is selected from the group consisting of an antibody, an aptamer, an antagonist, and a combination thereof capable of specifically binding to a protein of SHP-1/-2 or Fc.gamma.RIIB.

AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Pharmaceutical composition for preventing or treating neurodegenerative diseases

8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid has a protein tyrosine phosphatase 1B (PTP1B) inhibitory action, an Akt activating action, a GSK-3.beta. phosphorylation promoting action, and a suppressive action on .tau. protein phosphorylation induced by A.beta..sub.1-42, and is useful as a therapeutic drug for Alzheimer-type dementia, an antidepressant and/or an anti-aging drug.

dementia/phosphatase

Pharmaceutical composition for preventing or treating neurodegenerative diseases

Inhibitor of .tau. protein phosphorylation

La base de données d'herbes médicinales la plus complète soutenue par la science